1. Home
  2. AD vs STVN Comparison

AD vs STVN Comparison

Compare AD & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Array Digital Infrastructure Inc.

AD

Array Digital Infrastructure Inc.

N/A

Current Price

$46.87

Market Cap

4.3B

ML Signal

N/A

Logo Stevanato Group S.p.A.

STVN

Stevanato Group S.p.A.

HOLD

Current Price

$14.96

Market Cap

4.0B

ML Signal

HOLD

Company Overview

Basic Information
Metric
AD
STVN
Founded
1983
1949
Country
United States
Italy
Employees
4100
N/A
Industry
Telecommunications Equipment
Containers/Packaging
Sector
Telecommunications
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.3B
4.0B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
AD
STVN
Price
$46.87
$14.96
Analyst Decision
Strong Buy
Buy
Analyst Count
3
3
Target Price
$55.00
$25.67
AVG Volume (30 Days)
165.8K
467.8K
Earning Date
05-01-2026
03-04-2026
Dividend Yield
73.21%
0.43%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$9.67
Revenue Next Year
N/A
$9.99
P/E Ratio
$275.77
$27.15
Revenue Growth
N/A
N/A
52 Week Low
$44.03
$13.91
52 Week High
$77.13
$28.00

Technical Indicators

Market Signals
Indicator
AD
STVN
Relative Strength Index (RSI) 40.75 43.98
Support Level $46.61 $14.23
Resistance Level $50.23 $16.69
Average True Range (ATR) 1.25 0.81
MACD -0.18 0.04
Stochastic Oscillator 31.05 16.59

Price Performance

Historical Comparison
AD
STVN

About AD Array Digital Infrastructure Inc.

Array Digital Infrastructure, formerly US Cellular, sold its regional wireless operations serving about 4.4 million customers to T-Mobile in August 2025. The firm has agreed to sell most of its remaining spectrum licenses to Verizon and AT&T; however, it will still retain rights to C-band spectrum in several locations after these deals are closed. Array also owns a 5.5% stake in Verizon Wireless' Los Angeles operations and about 4,400 wireless towers.

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.

Share on Social Networks: